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STMN-1 is a potential marker of lymph node
metastasis in distal esophageal adenocarcinomas
and silencing its expression can reverse malignant
phenotype of tumor cells
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Abstract
Background: Distal esophageal adenocarcinoma is a highly aggressive neoplasm. Despite advances in diagnosis
and therapy, the prognosis is still poor. Stathmin (STMN-1) is a ubiquitously expressed microtubule destabilizing
phosphoprotein. It promotes the disassembly of microtubules and prevents assembly. STMN-1 can cause
uncontrolled cell proliferation when mutated and not functioning properly. Recently, found to be overexpressed in
many types of human cancers. However, its clinical significance remains elusive in distal esophageal
adenocarcinoma. Here, we reported for the first time that STMN-1 is highly overexpressed in adenocarcinomas of
the distal esophagus and strongly associated with lymph node metastasis.
Methods: STMN-1 expression in 63 cases of distal esophageal adenocarcinoma was analyzed by immunoblotting,
while expression in esophageal adenocarcinoma cells was determined by immunocytochemistry,
immunofluorescence, qRT-PCR and western blotting. Lentivirus-mediated RNAi was employed to knock-down
STMN-1 expression in Human esophageal adenocarcinoma cells. The relationship between STMN-1 expression and
lymph node metastasis in distal esophageal adenocarcinoma was determined by univariate and multivariate
analyses.
Results: STMN-1 was detected in 31 (49.21%) of the 63 cases. STMN-1 was highly overexpressed in specimens with
lymph node metastasis pN (+), but its expression was almost undetected in pN (−) status. Multivarian regression
analysis demonstrated that STMN-1 overexpression is an independent factor for lymph node metastasis in distal
esophageal adenocarcinoma. STMN-1 shRNA effectively reduced STMN-1 expression in esophageal adenocarcinoma
cells (P < 0.05), which significantly suppressed proliferation (P < 0.05), increased migration (P < 0.05) and invasion
ability (P < 0.05) and G1 phase arrest (P < 0.05) which lead to induction of apoptosis in esophageal adenocarcinoma
cells in vitro. To verify the in vitro data, we conducted in vivo tumor xenograft studies. Esophageal adenocarcinoma
cells stably transfected with STMN-1 shRNA significantly reduced tumor xenografts volume in vivo.
Conclusions: STMN-1 overexpression is associated with lymph node metastasis and increase malignancy in distal
esophageal adenocarcinoma. In vivo and in vitro laboratory findings, suggests that STMN-1 may be a suitable target
for future therapeutic strategies in distal esophageal adenocarcinoma.
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Background
Distal esophageal adenocarcinoma is a highly aggressive
neoplasm. Despite advances in diagnosis and therapy,
the prognosis of the patients is still poor. An estimated
16,640 new cases of esophageal cancer were diagnosed in
2010 in the United States with an estimated 14,500 deaths
[1] and an estimated 482,300 new cases and 406,800
deaths occurred in 2008 worldwide [2]. The World Health
Organization (WHO) predicts that by 2020, approximately
60% of all new cancer cases will occur in the least devel-
oped nations [3]. Most of the distal esophageal adenocar-
cinomas are of gastro-genic origin, which superiorly
invades the lower part of the esophagus or derived from
the malignant degeneration of Barrett’s esophagus. High
prevalence of esophageal squamous cell carcinoma with
poor prognosis has been well documented in Chinese
population. On clinical basis, distal esophageal adeno-
carcinoma is also a disease very commonly seen by the
thoracic surgeon. Perhaps due to obscure definition of
Gastric cardiac cancer and the lack of clear definition of
distal esophageal adenocarcinomas; the reports are not
commonly seen. In the 2009 UICC/AJCC TNM Classifi-
cation of Malignant Tumors, Esophageal cancer is rede-
fined as “Any tumor whose epicenter is in the lower
esophagus, gastroesophageal junction or proximal 5 cm
of the stomach that extends into the gastroesophageal
junction (GEJ) or esophagus” [4,5]. In the past, there were
no standard guidelines for distal esophageal adenocarcin-
omas lymph node clearance.
Adenocarcinomas of the distal esophagus have a high
propensity of lymph node metastasis and transcending
mucosal spread of disease. These are the main factors lim-
iting the curative potential of surgical treatment. There-
fore, investigating molecular biomarker to predict locally
advanced tumor with lymph node metastasis is significant
in the clinical practice. The current data showed us there
are no known identifiable molecular biological markers in
the early detection of metastasis in adenocarcinoma of the
distal esophagus. An understanding of the molecular basis
for the development of the distal esophageal adenocarcin-
oma is required to develop effective clinical diagnostic and
management strategies.
Surgical resection is the mainstay of therapy for esopha-
geal carcinoma; most patients are diagnosed at an unre-
sectable stage, particularly those with adenocarcinoma
of the distal esophagus. Given the poor prognosis and
the fact that most are diagnosed at a more advanced or
unresectable stage, new therapeutic strategies, treat-
ment options, and novel therapeutic targets are desper-
ately needed. Drug development has been transformed
with the identification of and ability to direct treatment
at specific molecular targets. In distal esophageal adeno-
carcinoma, development of novel targeted treatments is
lacking.
Stathmin 1 (STMN-1), also known as p17, p18, p19,
19 K, metablastin, oncoprotein 18, LAP 18 and Op18, is a
19 kDa cytosolic protein. Its function as an important
regulatory protein of microtubule dynamics has been well
characterized [6]. STMN-1 likely plays an important role
in cell cycle progression and cell migration. It has been re-
ported that STMN-1 is overexpressed in many human
malignancies, such as leukemia, lymphoma, neuroblast-
oma, ovarian, prostatic, breast and lung cancers [7] and
the modulation of its expression correlates with Invasion
and metastasis. STMN-1 gene expression in cancer cells
has been associated with their proliferation and metastasis
[8,9]. However, to our knowledge, no study has examined
the clinical significance of STMN-1 expression in adeno-
carcinoma of the distal esophagus.
The present study was initiated to evaluate STMN-1
expression in relation to lymph node metastasis in the
adenocarcinoma of the distal esophagus. The result
showed that STMN-1 expression correlates with lymph
node metastasis.
Multivariate logistic regression analysis demonstrated
that STMN-1 overexpression was an independent factor
of lymph node metastasis in distal esophageal adenocar-
cinoma. While we were confirming our clinical findings
through laboratory experiments, we also investigated the
function of STMN-1 gene in tumorgenesis and evaluated
the potential of STMN-1 as a therapeutic target for distal




For this study, specimens were examined from a total of 63
patients with resected distal esophageal adenocarcinoma
(Table 1). Patients ranged in age from < 40 years to ≥ 40
years and the median age was 57 years. Forty five were male
(71.43%) and 18 were female (28.57%). STMN-1 expression
was detected in 31 (49.21%) of the 63 distal esophageal
adenocarcinoma cases. Twenty nine patients (46%) were
diagnosed with pN1, N2 stage and 34 patients (54%) were
diagnosed with pN0 stage. Twenty one patients (33.33%)
were diagnosed with T1, T2 stage and forty two patients
(66.66%) with T3, T4a stage (Table 1).
STMN-1 expression in tumor samples
STMN-1 protein expression was analyzed in the distal
esophageal adenocarcinomas tissue in 63 patients. Western
blot analysis of samples showed that STMN-1 was up
regulated in 31 (49.21%) of the 63 cases. Twenty one pa-
tients (33.33%) with pN1 and pN2 were found positive
for STMN-1 and ten patients (15.87%) with pN0 also
showed overexpression of STMN-1 (Table 1).
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STMN-1 status and its correlation with patient
clinicopathological characteristics
Next, we investigated the association between STMN-1
expression and the clinicopathological characteristics of
distal esophageal adenocarcinoma cases and found that
STMN-1 overexpression was significantly associated
with pN classification (P = 0.001). The expression of the
STMN-1 protein in distal esophageal adenocarcinoma in
the pN1-pN2 stage was significantly higher than in the
pN0 stage and in the T3-T4a stage, it was significantly
higher than in the T1-T2 stage. However, no significant
correlation was found between STMN-1 expression and
gender, age, or degree of differentiation (Table 1).
STMN-1 expression positively correlates with pN stage in
adenocarcinoma of the distal esophagus
The relationship between STMN-1 status and clinico-
pathological features was investigated by univariate analysis.
STMN-1 protein expression was higher in node positive
vs. node negative specimen (P = 0.001) and locally advanced
(T3 +T4a) versus minimally advanced (T1 +T2) distal
esophageal adenocarcinoma (P = 0.004) but there was no
positive correlation with other clinicopathological charac-
teristics. Univariate analysis showed that STMN-1 gene ex-
pression is related to pN stage, and T classification in distal
esophageal adenocarcinoma. Multivariate analysis revealed
that only the pN stage is a significant factor, (P = 0.013)
as shown in Table 2.
STMN-1 expression in esophageal adenocarcinoma cell
lines
In the current study, we evaluated the state of STMN-1
protein expression in tissue samples by Western blot
analysis, (Figure 1A).
We further assessed the level of STMN-1 protein ex-
pression in esophageal adenocarcinoma derived cell lines
by immunocytochemistry (Figure 1B, C) and immuno-
fluorescence analysis (Figure 1D, E). Strong immunoreac-
tivity of STMN-1 protein was detected in the cytoplasm of
esophageal adenocarcinoma cells.
Transfection & transduction efficiency
Successful packing of lentivirus was done in HEK 293 T.
STMN-1 shRNA transfected cells and control shown
in (Figure 2A, B). To determines the efficacies of viral
vectors, viral supernatants prepared from either non-
silencing-shRNA (control) or STMN-1 shRNA were added
to esophageal adenocarcinoma cells. GFP expression in
photomicrographs of STMN-1-shRNA cells and control
Table 1 Clinicopathological characteristics of 63 distal
esophageal adenocarcinoma patients with STMN1
overexpression




Male 45 23 0.229 0.633
Female 18 8
Age at surgery
< 40 years 8 5 0.648 0.421
≥ 40 years 55 26
Weight loss
≥5 kg 14 8 0.454 0.501
<5 kg 49 23
Grade
Mild, High 48 22 0.918 0.338
Low 15 9
Stage (T)
T1, 21 5 8.129 0.004a
T3, T4a 42 26
Tumor greatest dimension
<3 cm 13 4 2.228 0.136
≥3 cm 50 27
Stage (N)
N0 34 10 11.579 0 .001a
N1,2 29 21
aStatistically significant.
Table 2 Multivariate logistic regression analysis
B S.E. Wald df Sig. Exp(B) 95.0% C.I. for EXP(B)
Factors Lower Upper
Gender 0.000 0.674 0.000 1 1.000 1.000 0.267 3.743
Age 1.294 0.952 1.845 1 0.174 3.646 0.564 23.577
Size 0.174 0.884 0.039 1 0.844 1.190 0.211 6.726
T status 1.096 0.754 2.110 1 0.146 2.991 0.682 13.114
N status 1.661 0.670 6.147 1 0.013a 5.263 1.416 19.559
Grade 0.646 0.729 0.787 1 0.375 1.909 0.458 7.964
Weightloss 0.739 0.778 0.902 1 0.342 2.094 0.456 9.616
aStatistically significant.
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shown in (Figure 2C, D, E, and F) confirmed > 90% trans-
duction efficiency. To evaluate the silencing efficiency
qRT-PCR and western blotting analysis were performed.
Lentivirus-mediated RNAi efficiently suppressed STMN-1
expression in esophageal adenocarcinoma cells
To investigate the role of STMN-1 in esophageal adeno-
carcinoma cell’s growth and metastasis, we constructed
lentivirus vector with STMN-1 shRNA and infected esopha-
geal adenocarcinoma cells. Stable expression of STMN-1
shRNAs specifically knocks down STMN-1 expression
and activity in esophageal adenocarcinoma cell. After
viral infection, more than 80% of the cells were GFP-
positive, indicating a high efficiency of shRNA delivery
(Figure 2C, D). The results of the western blot showed
that the average band intensities of STMN-1 normalized
to actin (Figure 3A).
Stable knockdown of oncogenic STMN-1 by lenti-shRNA
significantly inhibited esophageal adenocarcinoma cell’s
growth in vitro
To investigate the possible anti-proliferative effects of
STMN-1 knockdown in vitro, a CCK-8 assay was per-
formed and a cell growth curve was generated. STMN-1
shRNA transduced esophageal adenocarcinoma cells
showed significantly reduced viability relative to Non-
silencing control-transduced cells. STMN-1 knockdown
inhibited the proliferation of esophageal adenocarcinoma
cells in vitro, indicating that the differential STMN-1
gene expression affects the growth of esophageal adeno-
carcinoma cells (Figure 4A).
Figure 1 STMN1 expression in the distal esophageal adenocarcinoma tissue samples and cell lines. (A) Distal esophageal adenocarcinoma
tissue samples were lysed and immunoblotting was performed to detect expression of STMN1. Actin was used as loading control. STMN1
expression was low or negative in the samples obtained from the patients without lymph node metastasis (pN0) and pT1 classification but in the
patients with lymph node metastasis (pN+) status STMN1 was highly Overexpressed, some pT4a stage patients also showed moderate STMN1
expression. (B) Light microscopic immunocytochemistry revealed an intense cytoplasmic presence of STMN1 protein in esophageal cancer cells.
(C) Image at High-resolution showed strong cytoplasmic expression of STMN1. (D) Fluorescence microscopy of DAPI stained cells. (E) Immunofluorescent
images of distal esophageal adenocarcinoma cells labeled with an antibody against STMN1, the staining was repeated in triplicate three
independent times.
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Stable knockdown of STMN-1 expression inhibits
migration, invasion and metastasis of esophageal
adenocarcinoma cells
Cell migration was evaluated in the Boyden migration
assay two days after esophageal adenocarcinoma cells were
transfected with Non-silencing shRNA infected cells or
STMN1shRNA. STMN-1 shRNA transfected inhibited
migration (Figure 5A, B, C, D). To evaluate the function
of STMN-1 on Esophageal adenocarcinoma cell invasion,
Matrigel invasion chambers were utilized. Inhibited STMN-1
expression led to a significantly decreased invasive ability
of esophageal adenocarcinoma cells (Figure 5E).
Knockdown of STMN-1 expression induced cell cycle
arrest at the G1/S phase
The Flow cytometery results demonstrated that, STMN-1
shRNA treated cells induce an accumulation of esopha-
geal adenocarcinoma cells in the G1/S phase of the cell
cycle (Figure 4C, D). In the control group 48.6% of cells
were in the G1 phase and 46% of the cells were in S of
the cell cycle, and 24 post transfection, cells accumu-
lated in G1 54.4% but reduced to 40.5% in S phase.
These results demonstrate that knockdown of STMN-1
induces G1/S phase arrest in esophageal adenocarcin-
oma cells.
Figure 2 Transfection, Lenti-virus production and transduction. Co-transfection of the Trans-Lentiviral packaging mix with a shRNA transfer
vector into HEK293T packaging cells was done using Arrest-In Transfection Reagent. Following co-transfection, replication-incompetent virions
were released into the media which were collected after 48 h and 72 respectively. (A) Fluorescence microscopy image showing TurboGFP
expression from the pGIPZ STMN1 vector cells 72 h post-transfection. (B) Image showing the TurboGFP expression from the GIPZ Non-silencing
Control. (C) Phase contrast microscopy image. (D) TurboGFP images showing shRNA delivery efficiency. (E) & (F) post puromycine selection
images showing efficient transduction of Lenti-STMN1 shRNA in distal esophageal cancer cells.
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Knockdown of STMN-1 expression induced esophageal
adenocarcinoma cells apoptosis
As shown in Figure 4B, the percentage of apoptotic cells
infected with STMN-1 shRNA was much higher than
that in control shRNA group (P < 0.01). No significant
difference was found between control shRNA infected
cells and non-infected cells. These data indicated that
knockdown of STMN-1 expression induced apoptosis in
the esophageal adenocarcinoma cells.
In vivo studies of esophageal adenocarcinoma xenograft
tumor models in nude mice
To further evaluate the effects of reduced STMN-1 ex-
pression on the tumorigenic phenotype and in particu-
lar its contribution to in vivo tumor growth. Esophageal
adenocarcinoma cells infected with non-silencing shRNA
and STMN1 shRNA or untreated were injected into
mice, (Figure 6C, D). STMN1 shRNA transfected grew
rapidly as compared to negative control. These results
Figure 3 Verification of knockdown of STMN1 gene expression in esophageal cancer cell line by lentivirus-mediated RNA interference.
(A) Western blot analysis of STMN1 protein in lysates of either untreated (control) or transfected with a Non-silencing shRNA (scrambled sequence)
and transfected with a specific STMN1 shRNA. ACTIN expression was used as a loading control. (B) Densitometry analysis of A normalized to Actin,
Laser densitometric analysis of protein bands was performed, and the ratio of stathmin expression to Beta-Actin expression (STMN:Beta-Actin) was
determined and normalized. (C) Total RNA isolated from distal esophageal adenocarcinoma cells before and after silencing stathmin gene expression
using STMN1 shRNA were analyzed with real-time RT–PCR. There was no significant difference between controls and non-silencing shRNA (scrambled
sequences). Data are expressed as percentage change (Means ± S.D.) compared with controls and represent four independent experiments. (P < 0.05 vs
Non-silencing shRNA, one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparion).
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demonstrate that in vivo tumor growth was inhibited by
shRNA-mediated knockdown of STMN-1 expression in
esophageal adenocarcinoma cells.
Discussion
Stathmin 1 (STMN-1), also known as p17, p18, p19,
19 K, metablastin, oncoprotein 18, LAP 18 and Op18, is
a 19 kDa cytosolic protein. Its function as an important
regulatory protein of microtubule dynamics has been well
characterized [6]. It has been reported that STMN-1 is
overexpressed in many Human malignancies, such as
Leukemia, Lymphoma, Neuroblastoma, Ovarian, Prostatic,
Breast and Lung cancers [7] and the modulation of its ex-
pression correlates with invasion and metastasis. In our
study, we found that down regulating STMN-1 by specific
shRNA leads to reduction in STMN-1 protein expression
in esophageal cancer cells. STMN-1 has been implicated
in G1-S checkpoint control of cell cycle progression by in-
fluencing the dynamics of microtubule formation and pro-
gression of the cell cycle [10]. In human cancers, STMN-1
overexpression is associated with increased malignancy,
metastasis formation and decreased patient overall sur-
vival suggesting that STMN-1 could serve as a molecu-
lar marker to identify patients with more aggressive
disease [11]. Recent studies have shown that inhibition
of STMN-1 expression in malignant cells interferes with
their orderly progression through the cell cycle and abro-
gates their transformed phenotype [12]. Thus; STMN-1
provides an attractive molecular target for disrupting the
mitotic apparatus and arresting the growth of malignant
cells.
The protein expression of STMN-1 has been explored
and found to correlate to clinicopathologic factors and
poor prognosis in several cancers in different tissues such
as Brain [13], Oral mucosa [14], Breast [15-17], Urothelial
[18] as well as Ovarian [19], and Uterine cervix. So far, the
expression of STMN-1 has not been explored in distal
esophageal adenocarcinoma. To reveal a possible correl-
ation between STMN-1 up-regulation and lymph node
metastasis in distal esophageal adenocarcinoma, we exam-
ined the STMN-1 expression. We found that the expres-
sion of STMN-1 was positively correlated with lymph
node metastasis stages in distal esophageal adenocarcin-
oma (Tables 1, 2).
In this study, we first investigated the STMN-1 protein
expression in esophageal adenocarcinomas tissue (n = 63)
by western blotting analysis, and showed that STMN-1
was highly expressed in 31 (49.21%) of the 63 distal
Figure 4 Effects of STMN1 knockdown on cell growth and apoptosis. (A) Cells were transfected with Non-silencing shRNA as a negative control
or STMN1shRNA. Cell proliferation was measured by CCK-8. Data are expressed as percentage change (Means ± S.D.) compared with controls
and represent six independent experiments. (P < 0.05 vs Non-silencing shRNA, one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparion). (B) Apoptosis was assessed by TUNEL assay, the amount of DNA fragmentation (apoptosis) was assessed by TUNEL assay
for esophageal cancer cells before and after silencing stathmin gene expression utilizing STMN1 shRNA. There was no significant difference
between controls and non-silencing shRNA (scrambled sequences). Experiments were performed in triplicate. (C) Cell-cycle distributions of
control shRNA infected cells and (D) STMN1 shRNA infected cells as measured by flow cytometry.
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esophageal adenocarcinoma cases (Table 1). The level of
STMN-1 was significantly higher in esophageal cancer
tissue with lymph node metastasis pN(+) than pN(−).
Multivariate logistic regression analysis demonstrates
that the STMN-1 overexpression is an independent fac-
tor for lymph node metastasis in distal esophageal
adenocarcinoma (Table 2). On the basis of clinical re-
search, we found that STMN-1 was highly overex-
pressed in distal esophageal adenocarcinoma cases with
lymph node metastasis and advanced T classification.
This means that this gene can imply an aggressive ma-
lignancy of Adenocarcinoma. STMN-1 is up-regulated
in many neoplasms and the modulation of its expres-
sion correlates with invasion and metastasis [20].
Lymph node metastasis in distal esophageal adenocar-
cinoma has a worse prognosis. Therefore, it’s very im-
portant to uncover the necessary biological marker that
can predict early lymph node metastasis.
Laboratory research was conducted to correlate our
clinical findings. We used shRNA methodology to stably
silence the expression of STMN-1 in esophageal adenocar-
cinoma cells. Independent from its role in cell division,
STMN-1 has also been shown to regulate cell motility, en-
hance cell migration, and promote metastasis [20,21]. We
found that stable knockdown of STMN-1 led to reduced
proliferation rates and migration in vitro, and decreased
in vivo tumorigenicity.
Apoptosis, is a carefully regulated process that can be
induced by a variety of stimuli, including programmed
tissue remodeling, cell detachment (anoikis), genomic
damage, hypoxia, signaling pathway derangement,
growth factor or cytokine limitations, and infection
[22-24]. Dysregulation of apoptosis contributes to the
development of cancer, as decreased rates of cell death
facilitate an overall increase in cell number. For this
reason, the apoptotic pathway, similar to the cell cycle
proteins, has been an attractive target for therapeutic
development. Apoptosis is deregulated in many can-
cers, making it difficult to kill tumors. Drugs that re-
store the normal apoptotic pathways have the potential
for effectively treating cancers that depend on aberra-
tions of the apoptotic pathway to stay alive [25]. Apop-
tosis was significantly increased in STMN1 shRNA
knockdown cells.
RNA interference (RNAi) is a widespread and powerful
tool used for the functional regulation of gene expression,
and it has been developed as a potential therapeutic strat-
egy in various diseases, including cancers. However, the
knockdown effect of regular synthesized siRNA only lasts
for a short time and does not allow the stable inhibition
of target gene function. At the present time, for efficient
delivery and stable knockdown of target genes, lentiviral
vectors are the most appealing tool. The lentiviral vectors
for shRNA expression were used in our system. This
Figure 5 Effects of STMN1 knockdown on cell migration and invasion. The images of cells migrating PVPF filters as examined by cell
migration assay using Boyden chambers. Cell migration was evaluated in the Boyden migration assay two days after Esophageal cancer cells
were either (A) untreated or (B) transfected with Non-silencing shRNA or (C) stathmin1 siRNA. (D) Representing average of STMN1 shRNA
infected cells, Non-silencing shRNA infected cells and non-infected cells (P < 0.05) versus control. (E) The average invading cell counts of STMN1
shRNA infected cells, Non-silencing shRNA infected cells and non-infected cells. Data are expressed as percentage change (Means ± S.D.)
compared with controls and represent four independent experiments. (P < 0.05 vs Non-silencing shRNA, one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparion).
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approach allows for the stable suppression of target
gene expression both in cell culture conditions and in
animals.
STMN-1 increases the proliferation rate of leukemia
cells [26]. Our results showed that STMN-1 was directly
involved in cell proliferation and adhesion of esophageal
adenocarcinoma cells. STMN-1 expression in oral cancer
found to be correlated with tumour progression and poor
prognosis [14]. STMN-1 Up regulation increases the
aggressiveness of esophageal adenocarcinoma cells, and
enhances the migration ability which is responsible for
metastasis.
To validate effectiveness of down regulation of STMN-1
expression, we performed in vivo studies in nude mice;
our results showed that STMN-1 shRNA could effect-
ively down regulated STMN-1 expression by up to 85%
in esophageal adenocarcinoma cells with great specifi-
city (Figure 6C) indicating that the lentiviral-based
RNAi, because of its potency, could be utilized as an
effective strategy for cancer therapy. Additionally, the
blockage of proliferation in esophageal cell lines and
the inhibition of tumorigenesis in nude mice support
the effectiveness of this strategy.
STMN-1 is an indicator of lymph node metastasis in
distal esophageal adenocarcinomas and its silencing re-
verses the malignant biological behavior in esophageal
adenocarcinoma cells. These results suggest that expres-
sion of STMN-1 oncogene product may be associated
with the biological aggressiveness of adenocarcinomas of
the distal esophagus.
The results we describe herein provide new insights
for applying STMN-1 as a potential target for antitumor
therapy by silencing its expression with STMN-1 shRNA.
Cancer targets can be exploited by different strategies.
Thus far, the more successful clinical approaches have
been achieved with small-molecule drugs, monoclonal
antibodies, and protein kinase inhibitors. Of the new
anticancer drugs approved by the U.S. Food and Drug
Administration (FDA) since 2000, fifteen have been
targeted drug therapies, compared with only five trad-
itional chemotherapeutic agents. One of the promising
emerging technologies is RNAi, which is now being vig-
orously developed [27]. Current data from initial clinical
trials indicate that RNAi drugs will soon provide an-
other potent class of agents against malignant diseases
[28]. The pharmacologic validation of STMN-1 as a
Figure 6 Abdominal lymph node clearance and xenograft tumor models in nude mice. (A) Perigastric lymph nodes, lymph nodes along
the left gastric artery and lesser curvature lymph nodes dissection. (B) Distant abdominal lymph node dissection. Abdominal Esophagus drains
into superior gastric artery, celiac axis, common hepatic artery and splenic artery lymph nodes. (C) Esophageal cancer cells were either untreated
or transfected with Non-silencing shRNA (scrambled sequence) as a negative control and transfected with STMN1 shRNA were xenografted
subcutaneously in the BALB/c-nu/nu male mice. Tumor mass (xenograft) volume was measured every week from week 3 to week 7. Data are
expressed as percentage change (Means ± S.D.) compared with controls and represent four independent experiments. (P < 0.05 vs Non-silencing
shRNA, one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparion). (D) Photograph of xenografts dissected from nude mice
after 7 weeks subcutaneous inoculation showing suppression growth of cancer cells transfected with stathmin1 shRNA as compared to cells
transfected with untreated or transfected with Non-silencing shRNA.
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therapeutic target has not been fully elucidated because of
the lack of research in this area. Based on in vitro and
in vivo studies the shRNA targeting of STMN-1 has
shown to inhibit cell proliferation in vitro and tumor
growth in vivo. The potential outcome of STMN-1 inhib-
ition in cancer therapy is promising,
Conclusion
Our clinical data shows that increased STMN-1 expression
is associated with more aggressive disease, Thus, STMN-1
is an indicator of lymph node metastasis in distal esopha-
geal adenocarcinomas and it has oncogenic effects in cell
lines and xenografts. The differential expression status of
STMN-1 between the early and advanced pN stages of
distal esophageal adenocarcinoma may provide insights
into the process of tumorigenicity and for planning new
treatment strategies.
In summary, the results of the current study show that
using RNAi to reduce STMN-1 levels in esophageal can-
cer cells significantly reduced the expression of STMN-1
protein, cellular proliferation, migration, invasion, in vitro
and tumor growth in vivo. Further investigations are re-
quired to test which routes of delivery (e.g., direct intratu-
moral injections or systemic administration) of STMN-1




The study protocol was approved by the Ethics Committee
of Provincial Hospital Affiliated to Shandong University.
All the participants provided their written informed
consent for inclusion in the data analysis and manu-
script publication. Data were analyzed anonymously.
Patient selection and distal esophageal adenocarcinoma
specimen
From June 2010 to June 2012, sixty-three eligible patients
with previously untreated, potentially resectable, clinical
stage I-III distal esophageal adenocarcinomas were admit-
ted to the Department of Thoracic Surgery, Provincial
Hospital Affiliated to Shandong University, China. These
patients were all diagnosed with adenocarcinoma of the
distal esophagus. Complete clinical data, along with their
medical histories was kept in separate files for each patient
enrolled in the study. None of the patients had received
chemotherapy or radiotherapy prior to surgery. Informed
consent to obtain tissue samples for the study was taken
from each patient. Tissue samples were obtained at the
time of surgical resection. There were forty-five men and
eighteen women, and the median age was fifty-seven. The
age range was thirty-four to seventy-nine years old. To de-
fine the stage of adenocarcinoma of the distal esophagus,
we used TNM classification according to the 2009 UICC
standard [4].
Mice
BALB/C-nu/nu male mice (weight 18–22 g, 6 weeks old)
were obtained from the Shanghai Tumor Institution.
All experimental procedures using animals in the present
study had received prior approval by the Institutional
Animal Care and Use Committee of Shandong University
under Contract 2011–0015.
Cell lines, culture medium and reagents
Human Embryonic Kidney 293 cells (HEK93T) were
obtained from the Shanghai Tumor Institution. Human
esophageal adenocarcinoma cells were kindly provided
by the pathology department of provincial hospital. Clas-
sical Liquid Media Dulbecco’s Modified Eagles Medium
(DMEM), High Glucose RPMI Media 1640 was purchased
from HyClone (Thermo Scientific). Fetal bovine serum
(FBS) was purchased from Gibco (Invitrogen Co., USA).
Dimethyl sulfoxide (DMSO) was purchased from Sigma-
Aldrich (St Louis, Missouri, USA). Rabbit Anti-STMN1
Polyclonal antibody and HRP-conjugated secondary anti-
bodies were purchased from Abcam (Cambridge, MA).
Operation method
Patients were operated through the 7th intercostal space
with left posterolateral thoracotomy. The lower esophagus
was mobilized and periesophageal lymph nodes were
cleared. Thoracoabdominal two-field lymph node dissec-
tion was undertaken. An incision was made through the
diaphragm to enter the abdominal cavity. The greater and
lesser curvatures were mobilized. We routinely removed
perigastric lymph nodes, including left gastric artery node
(Figure 6A). For the nodal stations around the celiac tri-
furcation, we performed selective dissection when the
swollen lymph nodes were found or touched, and some-
times we only performed lymph node sampling when no
obviously swollen one was found (Figure 6B). From the
upper and lower margin of the tumor more than 5 cm
esophageal and gastric tissue were resected and then
Gastro-esophageal anastomosis was made mechanically
at the level of the inferior pulmonary vein. The average
age in this group was fifty-seven. This operation was
performed on forty-five males and eighteen females.
The average lymph node clearance was 21.5% per patient.
Cell culture
Esophageal adenocarcinoma cells were grown in RPMI
1640 medium supplemented with 10% fetal bovine serum
(FBS) and 100 units/ml penicillin, and 100 mg/ml strepto-
mycin. The cells were grown at 37°C in a humidified at-
mosphere containing 5% CO2. Stock cultures of each cell
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line were routinely sub-cultured at least once a week and
the medium was changed every 2–3 days.
Lentivirus-mediated short hairpin RNA (shRNA)
knockdown of gene expression
To knockdown STMN-1 expression, pGIPZ-lentiviral
shRNAmir vectors targeting human STMN1 and Non-
silencing pGIPZ control vector were purchased from
Open Biosystems (Thermo Fisher Scientific, Inc.). The
sequences of STMN-1 shRNA are as following: 5′-TTAT
TAGCTTCCATTTTGT-3′; 5′-TCTCTTCTATTGCCTT
CTG-3′ and 5′-TTATTAACCATTCAAGTCC-3′. Lentiviral
shRNA was produced by Co-transfection of the Trans-
Lentiviral packaging mix with a shRNA transfer vector
into HEK293T packaging cells (OpenBiosystems). For
cell infection, viral supernatants were supplemented
with 6 μg/mL polybrene and incubated with cells for 24
hours. Esophageal adenocarcinoma cell lines were trans-
duced by the lentiviral particles followed by puromycin se-
lection (1 μg/mL) for 10 days. The cells stably expressing
shRNA were maintained in puromycin (0.2 μg/mL).
RNA extraction and qRT-PCR
Total RNA extraction was performed using Trizol reagent
(Invitrogen) according to the manufacturer’s instruction.
RNA concentration was measured by Nano Drop 1000
(Thermo Fisher Scientific). One microgram of total RNA
extracted from the cells was subjected to reverse Tran-
scription (RT). Verso cDNA Ki (Thermo Scientific) was
used for cDNA synthesis. Real-time RT-PCR was used to
quantify the expression level of STMN-1 gene in Esopha-
geal adenocarcinoma cell line using ABI 7300 real-time
PCR thermal cycle instrument (ABI, USA), according to
the supplied protocol. Amplification conditions were as
follows: Reverse-transcription reaction: 42°C, 30 minutes
per cycle. PCR cycling conditions were as follows: Enzyme
activation 95°C 15 minutes per cycle, denaturation 95°C at
15 seconds per 40 cycles and Annealing/Extension at 60°C
for 60 seconds.
A Real-time PCR reaction was performed using the
Solaris qPCR Gene Expression Master Mix with LOW
ROX premixed and 1 μL of total cDNA in each well,
Stathmin specific primers were as follows:
(F, AGAATACACTGCCTGTCGCTTG; R, AGGCAC
GCTTCTCCAGTT). The relative expression levels were
normalized to expression of endogenous Beta-Actin. (Primers:
F, TGGAGAAAATCTGGCACCAC; R, GGTCTCAAA
CATGATCTGG).
Protein extraction and western blotting
For whole-cell protein extraction, esophageal adenocarcin-
oma cell line were washed with cold PBS and subsequently
lysed in cold RIPA lysis buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM dithiothreitol [DTT], 0.25% sodium
deoxycholate, 0.1% NP-40) containing 1 mM phenylmethy-
sulfonyl fluoride (PMSF), 50 mM sodiumpyrophosphate,
1 mM Na3VO4, 1 mM NaF, 5 mM EDTA, 5 mM EGTA,
and protease inhibitors cocktail (Roche). Cell lysis was
performed on ice for 30 minutes. Clear protein extracts
were obtained by centrifugation for 30 minutes at 4°C.
Protein concentrations were determined by the method
of Bradford using the Bio-Rad protein assay reagent
(Bio-Rad) and 20–40 mg of protein mixed with loading
buffer was loaded per lane, separated by 12% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). Pro-
teins were transferred to PVDF membrane filters (Millipore,
USA). Nonspecific binding was blocked by incubation in
phosphate-buffered saline (PBS) containing 0.1% Tween
20 (PBS-T) and 5% skim milk. PVDF membranes were
blocked with 5% dry milk for one hour at 4°C Membranes
were incubated in STMN-1 primary antibody (1:1000)
overnight at 4°C. The membranes were then incubated with
the corresponding secondary antibody (1:2000, horseradish
peroxidase-conjugated anti-rabbit) in TBST-5% nonfat milk
for 1 hour at room temperature and the immunoreactive
bands were visualized using EZ ECL Chemiluminescence
Detection Kit for HRP (Biological Industries Ltd, Israel).
Images were acquired using the LAS3000 Imager (Fujifilm).
Membranes were re-probed for Beta-Actin as a loading
control.
Cell proliferation assay
Cell Counting Kit-8 (CCK-8; Dojindo) was used in cell
proliferation assay. 3000 viable cells per well into 96-well
tissue culture plates in a final volume of 100 μl. Every 24
hours, a plate was subjected to assay by adding 10 μl of
CCK-8 solution to each well, and the plate was further in-
cubated for 4 hours at 37°C. The absorbance at 450 nm
was measured with a micro plate reader. The experiment
was performed in eight replicates.
Adhesion assay
Cell adhesion was analyzed using a Vybrant Cell Adhesion
Assay kit (Molecular Probes, USA) was used according to
the manufacter’s instructions. Briefly, cells in suspension
were labeled with Calcein AM dye, and equal numbers of
cells were plated in 96-well plates. At timed intervals,
non-adherent cells were removed and adherent cells were
quantified with the use of a SAFIRE fluorescence plate
reader.
Migration and invasion assays
For trans-well migration assay, 50,000 cells were added to
upper chamber in serum free media and migration at 37°C
towards 10% FBS containing growth media was deter-
mined either after 24 hours or 48 hrs. Cells migrated
through the membrane were fixed, stained with H&E
(Sigma) and counted under light microscope. For invasion
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assay, lower chambers of matrigel coated invasion plates
were coated with 10 mg/ml fibronectin overnight at 4°C
and cells invading through matrigel were fixed and stained
after 48 hours.
TUNEL assay
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (In Situ Cell Death Detection Kit POD)
was used for proving apoptosis in individual cells. The
TUNEL working procedure was carried out following the
producer’s directions (Roche). Endogenous peroxidase was
blocked by incubation in 1.3% H2O2 in PBS for 10 min at
room temperature before enzymatic labeling. During the
TUNEL procedure samples were washed in PBS. The
fluorescent signal conversion using anti-fluorescence anti-
body conjugated with peroxidase and substrate color reac-
tion applying chromogen DAB (3,3′-diaminobenzidine
tetrahydrochloride; Sigma-Aldrich, Germany) were pro-
ceeded after enzymatic labeling.
Flow cytometric cell cycle analysis
For cell cycle analysis esophageal adenocarcinoma cells
were collected in twenty-four post transfection, 6 cm plates.
Cells were harvested using cold PBS and fixed in 70% cold
ethanol overnight in 4°C and treated with 1 ng/ml RNase A
for 10 minutes at 37°C. Cellular DNA was stained with
15 ng/ml propidium iodide (PI) for 30 minutes at 37°C in
the dark. The cells then were sorted by FACS Calibur Flow
Cytometer (Becton Dickinson, CA) and cell-cycle profiles
were determined using the ModFitLT software (Becton
Dickinson, SanDiego, CA). The experiments were repeated
on two separate occasions.
Immunocytochemistry
Stably transfected esophageal adenocarcinoma cells were
seeded into 4-chambered glass slides (Nunc Lab-Tek
Chamber Slide System). Cells were then incubated over-
night. After 24 hours, cells were rinsed with PBS, fixed
with 3.7% w/v paraformaldehyde (Sigma), rinsed with PBS,
and permeablized in 0.5% Triton X-100 (Sigma). Nonspe-
cific immunoglobulin binding was blocked with 5% normal
goat serum and 0.5% NP-40 (Sigma). Primary antibodies
recognizing with STMN-1 (abicam) were diluted 1:100 in
blocking solution. After incubation with primary antibody,
cells were rinsed with 0.05% Tween-20 (Bio-Rad) in PBS,
and then incubated with secondary antibody for 1 h at RT.
Stain with 3,3′-Diaminobenzidine (DAB) and observed
under light microscope.
Immunofluorescence
To examine the protein expression of STMN-1 gene, we
performed immunofluorescence analysis. Briefly, the cells
were washed with PBS and fixed in 4% paraformaldehyde
for 10 minutes at 37°C followed by absolute methanol
for 10 minutes at 4°C and blocked in PBS containing 1%
skimmed milk for 10 minutes. The samples were then
incubated with affinity-purified Rabbit Anti-Human
STMN-1 Polyclonal Antibody (Abcam, USA) at a dilution
of 1: 100 for 2 hours, rinsed twice with PBS, and incubated
with goat anti-rabbit IgG Alexa Fluor 488 (Molecular
Probes) for 1 hour.
In vivo studies of esophageal adenocarcinoma cell line
xenograft tumor models in nude mice
Six-week-old male BALB/c nude mice were housed in a
temperature-controlled, pathogen-free animal facility with
12-hour light and dark cycles. Mice were injected subcuta-
neously into bilateral flanks with untransfected cells, or
transfected with Non-silencing shRNA and STMNEshRNA
(2 × 106 cells in 200 μl PBS) to establish tumors. Tumor
mass (xenograft) volume was measured every week from
week 3 to week 7. After 7 week mice were sacrificed, and
tumors were harvested.
Statistical analysis
For comparison of more than three groups, we used one-
way analysis of variance, followed by Tukey’s multiple
comparison-values < 0.05 were considered statistically sig-
nificant. One-way analysis of variance (ANOVA), followed
by the LSD post hoc test was used to compare mean dif-
ferences in 2 or more groups. Associations between cat-
egorical variables were evaluated by Pearson’s chi-square
test. P values represent 2- sided tests and are of statistical
significance when P < 0.05. These statistically significant
variables were found in the univariate analysis (P, 0.05),
and the Logistics Regression Model. Similar ratio statistics
were employed to further evaluate them for multivariate.
All statistical analysis was performed by using IBM SPSS
version 20.0.
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